Atorvastatin Tablet Crushing Guidance

Patient Selection and Monitoring

The American College of Cardiology recommends monitoring lipid levels periodically to ensure therapeutic efficacy is maintained when crushing atorvastatin tablets, as crushing may theoretically affect bioavailability 1
The American College of Cardiology suggests evaluating for muscle symptoms (soreness, tenderness, or pain) at 6-12 weeks after starting therapy and at each follow-up visit 2, 3
The American College of Cardiology advises checking ALT/AST levels initially, approximately 12 weeks after starting therapy, then annually or more frequently if indicated 2, 3
The American College of Cardiology recommends obtaining creatine kinase measurements when patients develop muscle symptoms 2, 3

The American Heart Association recommends avoiding combination with cyclosporine, tacrolimus, everolimus, or sirolimus without dose adjustment, as atorvastatin exposure can increase 6- to 15-fold with cyclosporine 4, 5, 6
The American Heart Association suggests limiting atorvastatin to ≤10 mg daily when combined with immunosuppressive agents, with close monitoring of creatinine kinase and muscle symptoms 4, 5, 6
The American College of Cardiology advises exercising caution with CYP3A4 inhibitors, including macrolide antibiotics, antifungal agents, and grapefruit juice, as atorvastatin is extensively metabolized by this pathway 2, 3